GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled TrialsLesley A. Inker, Tom Greene, Hiddo J.L. Heerspink et al.|Journal of the American Society of Nephrology|2019Cited by 295
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trialBrad H. Rovin, Catarina Almeida, Ulysses Diva et al.|The Lancet|2023Cited by 264
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trialHiddo J.L. Heerspink, Toby Coates, Jai Radhakrishnan et al.|The Lancet|2023Cited by 214